NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp
Next earnings Aug 12, 2026 · consensus $-0.22 EPS, $2.60M rev
Last earnings +1.4% on 2026-05-12
$3.34
▲ +4.38%$3.34▼ -15.91%
over 1Y
L $3.20EODHDH $6.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.4%
1W+2.8%
1M-10.5%
3M-24.2%
YTD-34.7%
1Y-15.9%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 163.5% YoY; but unprofitable (net margin -39.6%).
Revenue (FY2025) $9.10M · FY2025
NEUROONE MEDICAL TECHNOLOGIES Corp shows $9.10M in FY2025 revenue (+163.5% YoY), a -39.6% net margin, and -51.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $178K | $171K | $1.95M | $3.45M | $9.10M |
| Gross profit | -$97.7K | -$70.8K | $457K | $1.08M | $5.14M |
| Operating income | -$10.2M | -$10.0M | -$12.0M | -$11.9M | -$4.23M |
| Net income | -$9.95M | -$10.00M | -$11.9M | -$12.3M | -$3.61M |
| Diluted EPS | -$0.93 | -$0.63 | -$0.65 | -$0.46 | -$0.09 |
| Net margin | -5584.3% | -5842.0% | -607.4% | -356.7% | -39.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$163M
EV / EBITDA—
EV / Sales17.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.1%
FCF yield-1.7%
Quality & risk
ROIC (est.)-41.3%
Free cash flow-$2.92M
Total debt$1.01M
Net cash$5.56M
Altman Z-Score17.44 safe
Piotroski F-Score5/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+63.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-06-12). Worth a closer look.
- 8-K Other event2026-06-12
- 10-Q/A Restated periodic report2026-06-12
- 8-K Restatement (non-reliance)2026-05-22
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- 8-K Other event2026-05-04
- 8-K Officer / director change2026-04-30
- 8-K Charter / bylaws change2026-04-14
- DEF 14A Proxy statement2026-03-09
Recent filings
all on EDGAR ↗424B5Filing2026-06-12open ↗8-KPeriod ending 2026-06-122026-06-12open ↗10-Q/APeriod ending 2026-03-312026-06-12open ↗SDFiling2026-05-29open ↗SDFiling2026-05-29open ↗8-KPeriod ending 2026-05-212026-05-22open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗8-KPeriod ending 2026-04-302026-05-04open ↗8-KPeriod ending 2026-04-242026-04-30open ↗SCHEDULE 13GFiling2026-04-21open ↗8-KPeriod ending 2026-04-142026-04-14open ↗
Frequently asked
- Is NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) a buy?
- NMTC currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 163.5% YoY; but unprofitable (net margin -39.6%).
- What is NEUROONE MEDICAL TECHNOLOGIES Corp's quality score?
- NMTC scores 48.56862745098039/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001500198, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 1:12:24 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.